Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Erik Berg
Overview
- Gender
- male
Erik has over twenty years experience in the pharmaceutical industry. He is the CEO of AM-Pharma and board member of several (bio)tech companies. Previously, as a senior executive at Organon (currently Merck) he was responsible for leading the Company’s global biotechnology business development. Erik executed over 20 transactions and partnerships, most recently a $600M option to acquire AM-Pharma by Pfizer, and raised more than €130M in equity and debt financing. He concluded his masters in Chemistry from the University of Utrecht and an MBA from Manchester Business School both with honors.
Jobs
Number of Current Jobs
1
Erik Berg has 1 current jobs including
Chairman of the Board at Tridek-One
,
.
| Organization Name | Title At Company | Start Date | End Date | |
|---|---|---|---|---|
Tridek-One
|
Chairman of the Board | — | — | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
